Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2019 / Nov / Quick Hits (3)
Oncology Biochemistry and molecular biology Genetics and epigenetics Oncology Digital and computational pathology Molecular Pathology

Quick Hits

Discover the latest breakthroughs in pathology and laboratory medicine

By Luke Turner 11/24/2019 Quick Read (pre 2022) 1 min read

Share

Ductal carcinoma in situ – a premalignant breast cancer – is currently classed as low-, intermediate-, or high-risk. New research evaluated whether artificial intelligence can be used to distinguish between those risk categories, using quantitative nuclear histomorphometric features from H&E slides. Both tumor size and orientation from intermediate cases were found to be much more closely aligned with the low-risk than the high-risk group. Many intermediate patients currently receive radiation therapy, but these findings suggest that such an aggressive approach may not be necessary (1).

Data presented at the recent National Society of Genetic Counselors Annual Conference shows how more patients with genetic mutations can be identified by combining RNA and DNA tests compared with DNA testing alone. For the BRCA1 mutation commonly associated with breast cancer, the combination of RNA and DNA testing led to a 14 percent increase in the number of patients in whom cancer-linked mutations were identified. There was also a 4.5 percent relative decrease in the number of patients who would have received inconclusive results with only DNA testing (2).

A new contrast dye for magnetic resonance imaging (MRI) tests shows promise as an effective and noninvasive way to diagnose early-stage liver diseases. Contrast dyes improve visibility within the body during MRI, and the new ProCA32.collagen1 contrast agent targets the overexpression of collagen. Early tests in animal models have demonstrated its ability to detect early-stage alcohol-induced liver fibrosis and non-alcoholic steatohepatitis, the most severe form of non-alcohol fatty liver disease. Twice as accurate as conventional contrast agents, ProCA32.collagen1 can also detect tumors as small as 0.1 mm (3).

The sperm of infertile men have a specific epigenetic molecular signature attached to their DNA that fertile men lack, according to new research. Despite the increasing prevalence of male infertility worldwide, the current diagnostic procedure assesses sperm quantity and motility – a lengthy and often inaccurate approach. The signatures of differential DNA methylation regions associated with male idiopathic infertility problems may avoid long periods of uncertainty when diagnosing fertility issues. The researchers also uncovered a different biomarker within infertile patients that could indicate whether hormone therapy treatment may be effective (4).

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. H Li et al., “Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings”, Breast Cancer Res, 21, 114 (2019). PMID: 31623652.
  2. R Karam et al., “A Nationwide multi-center study provides insight into the increase in clinically actionable results from concurrent DNA and RNA genetic testing”. Poster presented at the 38th National Society of Genetic Counselors Annual Conference; November 6, 2019; Salt Lake City, USA. Poster #B-131.
  3. M Salarian et al., “Early detection and staging of chronic liver diseases with a protein MRI contrast agent”, Nat Commun, 10, 4777 (2019). PMID: 31664017.
  4. S Luján et al., “Sperm DNA methylation epimutation biomarkers for male infertility and FSH therapeutic responsiveness”, Sci Rep, 9, 16786 (2019). PMID: 31727924.

About the Author(s)

Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

More Articles by Luke Turner

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Biochemistry and molecular biology
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

Molecular Spectacular
Biochemistry and molecular biology
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

qPCR Infectious Disease Detective
Biochemistry and molecular biology
qPCR: Infectious Disease Detective

January 4, 2024

3 min read

How quantitative polymerase chain reaction really hits the mark in epidemic control and ID detection

Case of the Month
Biochemistry and molecular biology
Case of the Month

January 11, 2022

1 min read

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.